AVANT Adds Depth to Senior Management Team With Appointment of Michael Henry, Vice President Business Development

Apr 30, 2001, 01:00 ET from AVANT Immunotherapeutics, Inc.

    NEEDHAM, Mass., April 30 /PRNewswire/ -- AVANT Immunotherapeutics, Inc.
 (Nasdaq:   AVAN) today announced the appointment of Michael W. Henry as Vice
 President, Business Development.  Mr. Henry joins the Company from the
 University of Massachusetts Medical School, where he was Senior Director,
 Licensing and Ventures.
     At UMass Medical School, Mr. Henry was responsible for negotiating a large
 number of research collaborations, out-licensing agreements and new company
 formation arrangements with biotechnology, pharmaceutical and medical device
 companies.  At AVANT, Mr. Henry will be responsible for developing and
 implementing the Company's licensing and business development strategies.
 Previously, Mr. Henry has held business development and finance positions with
 US and Canadian based biotechnology companies.  Mr. Henry received a B.S. from
 the University of Michigan, an M.S. and an MBA from the University of
 California, Berkeley.
     "We are delighted that Mike has agreed to join us," said Una S. Ryan,
 President and Chief Executive Officer of AVANT Immunotherapeutics, Inc.
 "Mike's extensive business development experience in structuring and
 negotiating licensing deals with biopharmaceutical and life science companies
 will be invaluable as AVANT advances its products through development."
     AVANT Immunotherapeutics, Inc. is engaged in the discovery, development
 and commercialization of products that harness the human immune response to
 prevent and treat disease.  The company's most advanced therapeutic program
 focuses on compounds with the potential to inhibit inappropriate activation of
 the complement cascade, a vital part of the body's immune defense system.
 AVANT is also developing on its own a portfolio of oral vaccines aimed at
 protecting travelers from diseases endemic in developing areas, as well as a
 proprietary therapeutic vaccine for the management of cholesterol.  Through
 corporate collaborations, the company is additionally developing a variety of
 infectious disease vaccines.
     Additional information on AVANT Immunotherapeutics, Inc. can be obtained
 through our site on the World Wide Web:  http://www.avantimmune.com.
     Safe Harbor Statement Under the Private Securities Litigation Reform Act
 of 1995: This release includes forward-looking statements which reflect
 AVANT's current views with respect to future events and financial performance.
 The words "believe," "expect," "anticipate," and similar expressions identify
 forward-looking statements.  Investors should not rely on forward-looking
 statements because they are subject to a variety of risks, uncertainties, and
 other factors that could cause actual results to differ materially from those
 expressed in any such forward-looking statements.  These factors include, but
 are not limited to:  (1) the ability to successfully complete development and
 commercialization of products, including the cost, timing, scope and results
 of pre-clinical and clinical testing; (2) the ability to successfully complete
 product research and further development, including animal, pre-clinical and
 clinical studies; (3) the ability of the Company to manage multiple late stage
 clinical trials for a variety of product candidates; (4) the volume and
 profitability of product sales of Megan(R)Vac 1 and other future products; (5)
 changes in existing and potential relationships with corporate collaborators;
 (6) the cost, delivery and quality of clinical and commercial grade materials
 supplied by contract manufacturers (7) the timing, cost and uncertainty of
 obtaining regulatory approvals; (8) the ability to obtain substantial
 additional funding; (9) the ability to develop and commercialize products
 before competitors; (10) the integration of Megan Health's business and
 programs; (11) the ability to retain certain members of management; and (12)
 other factors detailed from time to time in filings with the Securities and
 Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X61734868
 
 

SOURCE AVANT Immunotherapeutics, Inc.
    NEEDHAM, Mass., April 30 /PRNewswire/ -- AVANT Immunotherapeutics, Inc.
 (Nasdaq:   AVAN) today announced the appointment of Michael W. Henry as Vice
 President, Business Development.  Mr. Henry joins the Company from the
 University of Massachusetts Medical School, where he was Senior Director,
 Licensing and Ventures.
     At UMass Medical School, Mr. Henry was responsible for negotiating a large
 number of research collaborations, out-licensing agreements and new company
 formation arrangements with biotechnology, pharmaceutical and medical device
 companies.  At AVANT, Mr. Henry will be responsible for developing and
 implementing the Company's licensing and business development strategies.
 Previously, Mr. Henry has held business development and finance positions with
 US and Canadian based biotechnology companies.  Mr. Henry received a B.S. from
 the University of Michigan, an M.S. and an MBA from the University of
 California, Berkeley.
     "We are delighted that Mike has agreed to join us," said Una S. Ryan,
 President and Chief Executive Officer of AVANT Immunotherapeutics, Inc.
 "Mike's extensive business development experience in structuring and
 negotiating licensing deals with biopharmaceutical and life science companies
 will be invaluable as AVANT advances its products through development."
     AVANT Immunotherapeutics, Inc. is engaged in the discovery, development
 and commercialization of products that harness the human immune response to
 prevent and treat disease.  The company's most advanced therapeutic program
 focuses on compounds with the potential to inhibit inappropriate activation of
 the complement cascade, a vital part of the body's immune defense system.
 AVANT is also developing on its own a portfolio of oral vaccines aimed at
 protecting travelers from diseases endemic in developing areas, as well as a
 proprietary therapeutic vaccine for the management of cholesterol.  Through
 corporate collaborations, the company is additionally developing a variety of
 infectious disease vaccines.
     Additional information on AVANT Immunotherapeutics, Inc. can be obtained
 through our site on the World Wide Web:  http://www.avantimmune.com.
     Safe Harbor Statement Under the Private Securities Litigation Reform Act
 of 1995: This release includes forward-looking statements which reflect
 AVANT's current views with respect to future events and financial performance.
 The words "believe," "expect," "anticipate," and similar expressions identify
 forward-looking statements.  Investors should not rely on forward-looking
 statements because they are subject to a variety of risks, uncertainties, and
 other factors that could cause actual results to differ materially from those
 expressed in any such forward-looking statements.  These factors include, but
 are not limited to:  (1) the ability to successfully complete development and
 commercialization of products, including the cost, timing, scope and results
 of pre-clinical and clinical testing; (2) the ability to successfully complete
 product research and further development, including animal, pre-clinical and
 clinical studies; (3) the ability of the Company to manage multiple late stage
 clinical trials for a variety of product candidates; (4) the volume and
 profitability of product sales of Megan(R)Vac 1 and other future products; (5)
 changes in existing and potential relationships with corporate collaborators;
 (6) the cost, delivery and quality of clinical and commercial grade materials
 supplied by contract manufacturers (7) the timing, cost and uncertainty of
 obtaining regulatory approvals; (8) the ability to obtain substantial
 additional funding; (9) the ability to develop and commercialize products
 before competitors; (10) the integration of Megan Health's business and
 programs; (11) the ability to retain certain members of management; and (12)
 other factors detailed from time to time in filings with the Securities and
 Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X61734868
 
 SOURCE  AVANT Immunotherapeutics, Inc.